Welcome to our store
When researching peptides, medications, or other biological compounds online, you may encounter terms such as FDA-approved, compounded, investigational, experimental, and research compound.
These terms can sound similar, but they describe very different things.
Understanding the difference matters because the regulatory status of a product does not simply tell you what the compound is—it also provides important information about how the product has been evaluated, how it may be marketed, and what conclusions can reasonably be drawn from available evidence.
For example, the U.S. Food and Drug Administration (FDA) explains that approved drugs undergo a formal review process involving information about safety, effectiveness, manufacturing, and labeling. Compounded drugs, on the other hand, are not FDA-approved and do not undergo the same premarket FDA review. (U.S. Food and Drug Administration)
Experimental or investigational compounds represent another category. These substances may be studied in laboratory research, animal studies, or human clinical trials, but being investigated does not mean that the compound has been approved for marketing.
This guide explains these categories in straightforward terms and shows why regulatory status and scientific evidence should be considered separately.
An FDA-approved drug has gone through the FDA’s drug review process for a specific intended use.
The approval process involves evaluating evidence submitted by the drug sponsor. This can include laboratory and animal research, human clinical trial data, information about manufacturing, and proposed labeling. FDA explains that its review considers whether the drug is safe and effective for its proposed use and whether the manufacturing process can consistently produce the drug with appropriate quality. (U.S. Food and Drug Administration)
FDA approval therefore represents a specific regulatory determination.
It does not mean that a drug is suitable for every person or every possible use.
Instead, approval is connected to the particular product, its intended use, available evidence, labeling, and regulatory requirements.
This distinction becomes especially important when discussing compounds online.
A compound may have an FDA-approved version for one specific indication while a different formulation, use, or product is not necessarily covered by that approval.
Compounding is a process in which ingredients are combined, mixed, or altered to create a medication intended to meet a particular need.
FDA gives examples such as a patient who cannot use an ingredient contained in an FDA-approved medicine or a patient who needs a dosage form that is not commercially available. (U.S. Food and Drug Administration)
Compounding can therefore have a legitimate role in healthcare.
However, an important point is often misunderstood:
FDA explicitly states that compounded drugs are not FDA-approved and therefore do not undergo FDA premarket review for safety, effectiveness, or quality in the same way as approved drugs. (U.S. Food and Drug Administration)
That does not mean that every compounded drug is automatically unsafe or that compounding itself is illegitimate.
Rather, it means that the regulatory pathway is different from the pathway used for an FDA-approved drug.
There are situations where an FDA-approved medication may not meet a particular patient’s needs.
For example, a patient could have an allergy to a particular inactive ingredient or have difficulty swallowing a particular dosage form.
In such situations, a compounded medication may sometimes be prepared to address the specific medical need.
FDA recognizes that compounding can serve an important role for certain patients. At the same time, the agency notes that compounded products can carry quality risks because they do not undergo the same premarket FDA review as approved drugs. (U.S. Food and Drug Administration)
This is an important distinction for educational content:
“Not FDA-approved” does not automatically mean “illegal” or “unsafe.”
It means the product has a different regulatory status and has not gone through the FDA’s premarket approval process for an approved drug.
An experimental or investigational compound is generally a substance being studied to determine whether it may have useful biological or medical applications.
Researchers may study a compound at several stages.
Early research may involve:
If researchers have sufficient preliminary information, investigation may progress to studies involving humans.
FDA describes clinical research as research conducted in people and explains that drug developers generally use the Investigational New Drug (IND) process before beginning clinical research involving an investigational drug, subject to applicable requirements and exemptions. (U.S. Food and Drug Administration)
An investigational compound can therefore be part of legitimate scientific research without being an approved medicine.
This is one of the most important concepts to understand.
A compound can be the subject of scientific research without having FDA approval for marketing.
For example, researchers may investigate a molecule because laboratory experiments suggest that it interacts with a particular biological pathway.
That can be an interesting scientific observation.
However, additional research may still be needed to determine:
FDA’s drug-development framework separates preclinical research, clinical research, FDA review, and post-market safety monitoring into different stages. (U.S. Food and Drug Administration)
This is why a scientific paper describing an experimental compound should not automatically be interpreted as evidence that the compound is an approved treatment.
The term Investigational New Drug (IND) is used within the U.S. regulatory system.
An IND application is used when a drug or biological product that has not previously been authorized for marketing in the United States is intended for clinical investigation, subject to the applicable regulatory requirements. (U.S. Food and Drug Administration)
The application can contain information such as:
FDA explains that the IND process is designed to allow regulators to assess whether proposed clinical research can proceed without exposing participants to unreasonable risks. (U.S. Food and Drug Administration)
Importantly, an IND is not the same thing as marketing approval.
An investigational drug can be studied in clinical research while remaining unapproved for general marketing.
Drug development is a lengthy process.
A simplified pathway looks like this:
Discovery and development
↓
Preclinical laboratory and animal research
↓
Investigational New Drug process
↓
Human clinical research
↓
Regulatory review
↓
Potential approval
FDA describes drug development as a sequence that includes discovery and development, preclinical research, clinical research, FDA review, and post-market safety monitoring. (U.S. Food and Drug Administration)
Each stage answers different questions.
Early laboratory research can help scientists understand biological mechanisms.
Animal research can provide additional information about pharmacology and safety.
Clinical trials provide information from human participants.
Regulatory review then considers the complete evidence submitted for the proposed use.
Laboratory and animal studies are important parts of research, but they cannot answer every question about how a compound will perform in humans.
FDA notes that preclinical research helps answer basic safety questions but is not a substitute for studies of how a drug interacts with the human body. Clinical research involves studies conducted in people. (U.S. Food and Drug Administration)
Human clinical trials may investigate different aspects of a compound, including:
Researchers monitor participants for adverse events and other safety concerns.
Researchers assess how participants respond to the intervention.
Studies may examine how the compound behaves inside the body.
Depending on the trial and stage of development, researchers may investigate whether the intervention produces a meaningful effect for a specific condition.
Researchers may investigate how different doses relate to safety and biological or clinical outcomes.
The design of the study matters just as much as the name of the compound.
A common mistake when researching experimental compounds is assuming that scientific discussion equals regulatory approval.
It does not.
A compound can appear in:
None of these automatically means that the compound is FDA-approved.
Regulatory approval is a separate process.
FDA explains that an NDA is the formal application through which a sponsor asks the agency to approve a new pharmaceutical for marketing in the United States. The submission includes relevant animal and human data as well as information about manufacturing and the proposed use. (U.S. Food and Drug Administration)
Therefore, when reading about a compound, it is useful to ask two separate questions:
What does the scientific evidence say?
and
What is the regulatory status?
Those questions are related, but they are not identical.
No.
These terms describe different concepts.
A compounded drug is a medication prepared through a compounding process under applicable legal and regulatory frameworks.
An experimental or investigational compound refers to a substance being studied to understand its effects, safety, or potential uses.
A compounded drug can involve a medication that has an FDA-approved counterpart, while the compounded product itself remains not FDA-approved.
An investigational compound may be completely new and still undergoing development.
The categories can therefore overlap in discussions about a particular substance, but they should not be treated as interchangeable terms.
The same principles apply to peptides.
A peptide may be investigated in laboratory research, animal models, or human clinical studies.
But the word “peptide” by itself tells you very little about its regulatory status.
Some peptide-based products are approved medicines.
Other peptides may be experimental.
Others may be used in research settings.
The correct approach is to identify the specific compound, the specific product, the specific intended use, and the evidence supporting that use.
This is particularly important because online discussions sometimes combine scientific findings with conclusions about medical applications that have not been established.
When researching a compound, consider the following checklist.
Check the full name, development code, formulation, or other identifying information.
For U.S. questions, FDA resources are an important starting point.
If it is approved, identify the approved indication and formulation.
If a product is compounded, remember that the compounded product itself is not FDA-approved. (U.S. Food and Drug Administration)
Look for clinical research and published scientific literature.
Do not rely solely on marketing language or summaries.
Ask whether the evidence comes from cells, animals, humans, or multiple replicated studies.
For more information, see our related guide:
That article explains how to distinguish different types of scientific evidence and why the level of evidence matters.
Regulatory status provides important context.
An FDA-approved drug has passed through a formal regulatory review for its approved use.
A compounded drug has a different regulatory pathway and is not FDA-approved.
An investigational compound is being studied and has not necessarily established the safety and effectiveness required for approval.
These distinctions help readers interpret scientific information more accurately.
They also help prevent a common mistake: assuming that because a compound is mentioned in a scientific publication, it has already been established as an approved treatment.
Scientific research is part of the process.
Regulatory approval is a separate determination based on the evidence submitted for the proposed product and use.
No. FDA-approved drugs undergo FDA review for their approved uses. Compounded drugs are not FDA-approved and do not undergo the same premarket FDA review. (U.S. Food and Drug Administration)
No. Compounding can serve legitimate medical needs. However, FDA notes that compounded drugs have different regulatory oversight and can present quality risks, including contamination or incorrect strength. (U.S. Food and Drug Administration)
Not necessarily. Experimental or investigational compounds may be studied without being approved for marketing.
No. An IND relates to the process for conducting certain clinical investigations. It is not the same as FDA marketing approval. (U.S. Food and Drug Administration)
Not by itself. The answer depends on the type, quality, design, and results of the research. Laboratory, animal, and human studies provide different kinds of evidence.
It provides context about where a product or compound stands within the U.S. regulatory framework and helps readers distinguish established approved uses from research or compounded products.
The terms approved, compounded, and experimental should not be treated as interchangeable.
An FDA-approved drug has undergone a formal regulatory review for a particular use.
A compounded drug is prepared through a compounding process and, according to FDA, is not itself FDA-approved.
An experimental or investigational compound is being studied to determine its properties, safety, biological activity, or potential medical applications.
The most useful way to evaluate information about any compound is to consider both scientific evidence and regulatory status.
Scientific papers can tell us what researchers observed. Clinical trials can provide evidence from human participants. Regulatory information can explain whether a particular product has been reviewed and approved for a particular use.
Understanding the difference helps readers interpret research more accurately and avoid confusing scientific investigation with regulatory approval.
For the next step, read our related guide:
It explains the differences between cell research, animal studies, human trials, and replicated evidence—and provides a useful framework for evaluating claims about research compounds and peptides.
© 2026 All rights reserved
